Generics - Teva Pharmaceutical Industries, Anti-virals


Popular Filters

Mixed US court decision on ViiV Healthcare’s Epzicom and Trizivir patents


UK pharma giant GlaxoSmithKline and ViiV Healthcare confirmed that the US District Court for the District…

Anti-viralsEpzicomGenericsGlaxoSmithKlineLegalLupinPatentsTeva Pharmaceutical IndustriesTrizivirViiV Healthcare

Gilead and Teva settle Viread patent litigation


US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Bristol-Myers gets $438 million under Latin America OTC deal with Reckitt Benckiser; Baraclude patent ruled invalid


US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a three-year collaboration agreement…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLicensingNorth AmericaPatentsPharmaceuticalReckitt BenckiserSouth AmericaTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Company Spotlight



Back to top